Study summary
Eltrombopag beat steroids or IVIG as first treatment for children with ITP
65%sustained platelet response, vs 35%
What was tested
Eltrombopag, a daily pill that boosts platelet production, against standard first-line treatment (steroids, IVIG or anti-D), for children with newly diagnosed ITP needing treatment.
What they found
- Sustained platelet response: 65% with eltrombopag vs 35% with standard therapy.
- The trial stopped early for efficacy; side effects were similar.
What it means
May move platelet-boosting pills earlier in children.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.